What is the recommended management for an adult with CKD (chronic kidney disease), including blood pressure control, proteinuria, diabetes, and stage‑specific therapy?

Management of Chronic Kidney Disease

Adults with CKD require a comprehensive strategy addressing blood pressure control, proteinuria reduction, diabetes management, and stage-specific complications, with SGLT2 inhibitors and RAS blockade forming the cornerstone of modern therapy.

---

Blood Pressure Management

Target Blood Pressure

• Aim for <130/80 mmHg in patients with albuminuria ≥30 mg/day (or ACR ≥30 mg/g) because this target provides optimal cardiovascular and renal protection. 1
• For patients without significant albuminuria (<30 mg/day), target <140/90 mmHg as lower targets have not demonstrated additional kidney or cardiovascular benefit in this population. 1, 2
• The <120 mmHg systolic target applies only when standardized automated office blood pressure measurement is used (5-minute rest, average of three readings); applying this to routine office measurements leads to overtreatment. 1, 3

First-Line Antihypertensive Therapy

• Initiate an ACE inhibitor for all CKD patients with albuminuria ≥300 mg/day (strong 1B recommendation). 1
• For moderately increased albuminuria (30-300 mg/day), start either an ACE inhibitor or ARB as first-line therapy. 1
• If an ACE inhibitor is not tolerated due to cough or angioedema, substitute an ARB as renal and cardiovascular benefits are comparable. 1
• Titrate the ACE inhibitor or ARB to the maximum approved dose that the patient tolerates because trial benefits were achieved at these doses. 1, 2

Monitoring After RAS Inhibitor Initiation

• Check serum creatinine, eGFR, and potassium 2-4 weeks after starting or uptitrating an ACE inhibitor or ARB. 1, 2
• Continue the RAS inhibitor unless serum creatinine rises >30% within 4 weeks; a rise up to 30% reflects the intended hemodynamic effect and predicts long-term renoprotection. 1
• Manage hyperkalemia with potassium-wasting diuretics, potassium binders, or dietary restriction rather than stopping the RAS inhibitor. 1
• Reduce the dose or discontinue only if hyperkalemia is uncontrolled despite measures, symptomatic hypotension develops, or creatinine increase >30% persists. 1

Add-On Antihypertensive Agents

• Add a thiazide-like diuretic (chlorthalidone or indapamide) or a dihydropyridine calcium-channel blocker (amlodipine) as second-line therapy when blood pressure remains uncontrolled on ACE inhibitor/ARB monotherapy. 1, 3
• For CKD stage 4-5, use loop diuretics instead of thiazides due to reduced efficacy of thiazides at lower eGFR. 3
• Most CKD patients require three or more antihypertensive agents to achieve target blood pressure. 3, 4
• For resistant hypertension, add a mineralocorticoid receptor antagonist (spironolactone or eplerenone) with close monitoring for hyperkalemia. 1, 3

Critical Contraindications

• Never combine an ACE inhibitor with an ARB (dual RAS blockade) because it increases hyperkalemia, hypotension, and acute kidney injury without added benefit (strong 1B recommendation against). 1
• Avoid triple RAS blockade (ACE inhibitor + ARB + direct renin inhibitor) as it further increases adverse events. 1, 2

---

SGLT2 Inhibitors

Indications and Dosing

• Treat adults with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² with an SGLT2 inhibitor (strong 1A recommendation). 1
• Treat adults with CKD and eGFR ≥20 mL/min/1.73 m² who have either ACR ≥200 mg/g or heart failure with an SGLT2 inhibitor, irrespective of diabetes status (strong 1A recommendation). 1
• Consider an SGLT2 inhibitor for adults with eGFR 20-45 mL/min/1.73 m² and ACR <200 mg/g (suggested 2B recommendation). 1

Monitoring and Safety

• Once initiated, continue the SGLT2 inhibitor even if eGFR falls below 20 mL/min/1.73 m² unless it is not tolerated or kidney replacement therapy is initiated. 1
• Withhold SGLT2 inhibitors during prolonged fasting, surgery, or critical medical illness when patients may be at greater risk for ketosis. 1
• The reversible decrease in eGFR on initiation is generally not an indication to discontinue therapy and does not necessitate alteration of CKD monitoring frequency. 1

---

Nonsteroidal Mineralocorticoid Receptor Antagonists

• Consider a nonsteroidal MRA (finerenone) for adults with type 2 diabetes, eGFR >25 mL/min/1.73 m², normal potassium, and albuminuria >30 mg/g despite maximum tolerated RAS inhibitor (suggested 2A recommendation). 1
• Nonsteroidal MRAs are most appropriate for adults with type 2 diabetes at high risk of CKD progression and cardiovascular events as demonstrated by persistent albuminuria despite other standard-of-care therapies. 1
• A nonsteroidal MRA may be added to a RAS inhibitor and an SGLT2 inhibitor for treatment of type 2 diabetes and CKD. 1

---

Diabetes Management in CKD

Glycemic Control

• Maintain HbA1c targets individualized to the patient's CKD stage, hypoglycemia risk, and life expectancy because intensive glucose control requires 2-10 years to manifest as improved eGFR outcomes. 1
• Metformin is not contraindicated in CKD; the FDA revised guidance in 2016 to allow use based on eGFR rather than serum creatinine, expanding the pool of patients for whom metformin should be considered. 1

Medication Selection

• SGLT2 inhibitors and GLP-1 receptor agonists have direct kidney-protective effects independent of glycemia, including reduction of intraglomerular pressure, albuminuria, and oxidative stress. 1
• Medication dosing may require modification when eGFR <60 mL/min/1.73 m² to avoid hypoglycemia and drug accumulation. 1

---

Lifestyle Modifications

• Limit dietary sodium to <2 g/day (≈5 g salt) because patients with albuminuria are often salt-sensitive and sodium restriction enhances the antiproteinuric effect of RAS inhibitors. 1, 3
• Restrict protein intake to ≈0.8 g/kg/day for CKD stages 3-5 and avoid high-protein diets >1.3 g/kg/day that may accelerate kidney function decline. 1, 3
• Encourage at least 150 minutes per week of moderate-intensity physical activity. 3
• Advise tobacco cessation. 3
• Maintain a healthy body weight appropriate for age and comorbidities. 3

---

Monitoring and Follow-Up

Frequency of Monitoring

• For CKD stage 3a, check eGFR and serum creatinine at least annually (typically 2-4 times per year) and measure urine albumin-to-creatinine ratio annually to detect new-onset albuminuria. 3, 4, 5
• For CKD stage 3b and higher, monitor eGFR, serum creatinine, urine ACR, and serum potassium more frequently based on albuminuria category and medication regimen. 1, 3
• Schedule clinic visits every 6-8 weeks until blood pressure target is achieved, then follow up every 3-6 months based on medication regimen and patient stability. 3

Laboratory Monitoring

• Repeat a basic metabolic panel 2-4 weeks after adding or adjusting any agent that affects electrolytes or renal function (ACE inhibitor, ARB, diuretic, MRA). 1, 3
• Monitor for complications of CKD including hyperkalemia, metabolic acidosis, hyperphosphatemia, vitamin D deficiency, secondary hyperparathyroidism, and anemia. 4

Home Blood Pressure Monitoring

• Implement home blood pressure monitoring during medication titration to prevent hypotension (systolic <110 mmHg). 3
• Assess patients for symptoms of hypotension such as fatigue, light-headedness, or dizziness at each visit. 1, 3

---

Nephrology Referral

• Refer patients at high risk of CKD progression promptly to a nephrologist: those with eGFR <30 mL/min/1.73 m², albuminuria ≥300 mg per 24 hours, or rapid decline in eGFR. 4
• Consider referral for poorly controlled blood pressure, suspected inherited renal disease, or uncertainty about CKD etiology. 5

---

Patient Education: Sick-Day Management

• Instruct patients to hold or reduce antihypertensive doses during acute illnesses with vomiting, diarrhea, or reduced oral intake to prevent volume depletion and acute kidney injury. 3
• Teach patients to watch for symptoms of hypotension such as fatigue, light-headedness, or dizziness. 3

---

Avoidance of Nephrotoxins

• Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) in CKD patients because they antagonize the renal protective effects of RAS blockade and increase the risk of acute kidney injury. 2, 4
• Adjust dosing of renally cleared medications (many antibiotics, oral hypoglycemic agents) based on eGFR. 4

---

Special Populations

Elderly and Frail Patients

• Chronological age alone should not preclude appropriate blood pressure control; frail elderly patients in the SPRINT trial achieved the same cardiovascular and mortality benefit from intensive blood pressure lowering as younger patients. 3
• Patients with symptomatic postural hypotension or limited life expectancy may require less intensive blood pressure targets; check orthostatic vital signs at every visit. 1, 3

Children with CKD

• Initiate blood pressure-lowering treatment when BP is consistently above the 90th percentile for age, sex, and height (strong 1C recommendation). 1
• Lower BP to consistently achieve systolic and diastolic readings ≤50th percentile for age, sex, and height unless achieving these targets is limited by signs or symptoms of hypotension (suggested 2D recommendation). 1
• Use an ACE inhibitor or ARB as first-line therapy in children with CKD irrespective of the level of proteinuria (suggested 2D recommendation). 1, 2

Kidney Transplant Recipients

• Target blood pressure <130/80 mmHg using standardized office measurement. 1
• Use a dihydropyridine calcium-channel blocker or an ARB as first-line therapy considering time post-transplant and calcineurin-inhibitor use. 1, 3
• In patients receiving mTORC1 inhibitors, prefer an ARB over an ACE inhibitor because it carries a lower risk of angioedema. 2

---

Common Pitfalls to Avoid

• Do not apply the <120 mmHg target to routine office blood pressure measurements; it requires standardized automated measurement (5-minute rest, average of three readings). 1, 3
• Do not discontinue an ACE inhibitor/ARB for a creatinine rise <30%; this reflects the intended hemodynamic effect and predicts long-term renoprotection. 1, 3
• Never combine an ACE inhibitor with an ARB as this increases harm without benefit. 1
• Do not withhold ACE inhibitor/ARB therapy when eGFR falls below 30 mL/min/1.73 m²; continue therapy unless specific contraindications arise. 1
• Recognize that small changes in eGFR may represent progressive CKD rather than acute kidney injury; attend to other clinical indicators to differentiate these entities. 1